Kymera Therapeutics Reports $65M Collaboration Revenue in Q2 2026, Net Loss of $61.2M

Kymera Therapeutics, Inc. reported significant financial developments in its latest 10-Q filing for the second quarter of 2026. The company generated collaboration revenue of $65 million for the three months ended June 30, 2026, a substantial increase from $11.5 million in the same period last year. For the first half of 2026, total collaboration revenue reached $99.4 million, compared to $33.6 million in the first half of 2025. This growth is attributed primarily to the successful execution of collaboration agreements with Gilead and Sanofi, including a $45 million option exercise payment from Gilead.

Despite the increase in revenue, Kymera's operating expenses also rose significantly, totaling $140.6 million for the second quarter of 2026, up from $96 million in the prior year. Research and development expenses accounted for the majority of this increase, rising to $119.5 million from $78.4 million, driven by heightened investment in clinical programs, particularly those targeting STAT6. General and administrative expenses also increased to $21.1 million from $17.6 million, reflecting higher legal and professional service fees as well as increased personnel costs. The net loss for the quarter was $61.2 million, an improvement from the $76.6 million loss reported in the same quarter of 2025.

Operationally, Kymera continues to expand its clinical pipeline, focusing on targeted protein degradation therapies. The company is advancing multiple programs, including KT-621 and KT-579, which are currently in various stages of clinical trials. As of June 30, 2026, Kymera had cash, cash equivalents, and marketable securities totaling $1.5 billion, which the company believes will be sufficient to fund operations into 2029. This financial cushion is expected to support ongoing clinical trials and the development of new product candidates.

The company’s employee headcount has also increased, reflecting its commitment to expanding research and development capabilities. As of the latest filing, Kymera has not yet commercialized any products and continues to rely on collaboration agreements for revenue generation. The company anticipates that it will continue to incur operating losses until it can successfully develop and commercialize its product candidates. Looking ahead, Kymera plans to finance its operations through a combination of equity offerings, collaborations, and other strategic transactions, although it acknowledges the challenges of raising additional funds in the current market environment.

In summary, Kymera Therapeutics is experiencing growth in collaboration revenue alongside rising operational costs, as it advances its clinical programs and prepares for future commercialization efforts. The company remains focused on leveraging its financial resources to support ongoing research and development while navigating the complexities of the biopharmaceutical landscape.